Creatine for Parkinson's disease

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 6, 2014, Pages

  Xiao, Yousheng ^a   Luo, Man ^a   Luo, Hongye ^a   Wang, Jin ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; PLACEBO; NEUROPROTECTIVE AGENT;

ADJUVANT THERAPY; DAILY LIFE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; MEDICAL DECISION MAKING; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIABILITY; REVIEW; SAMPLE SIZE; STATISTICAL BIAS; SYSTEMATIC REVIEW; META ANALYSIS;

ACTIVITIES OF DAILY LIVING; CREATINE; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84942788002     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009646.pub2     Document Type: Review

References (31)

1. Bender A, Koch W, Elstner M, Schombacher Y, Bender J, Moeschl M, et al.Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 2006;67(7):1262-4.
2. Bender A, Samtleben W, Elstner M, Klopstock T. Long-term creatine supplementation is safe in aged patients with Parkinson disease. Nutrition Research 2008;28(3):172-8.
3. NINDS NET-PD Investigators. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clinical Neuropharmacology 2008;31(3):141-50.
4. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006;66(5):664-71.
5. Parashos SA, Swearingen CJ, Biglan KM, Bodis-Wollner I, Liang GS, Ross GW, et al.Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. Archives of Neurology 2009;66(9):1099-104.
6. Hass CJ, Collins MA, Juncos JL. Resistance training with creatine monohydrate improves upper-body strength in patients with Parkinson disease: a randomized trial. Neurorehabilitation and Neural Repair 2007;21(2):107-15.
7. Elm JJ, NINDS NET-PD Investigators. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Movement Disorders 2012;27(12):1513-21.
8. NINDS NET-PD Investigators. A Multicenter, Double-Blind, Parallel Group, Placebo Controlled Study of Creatine in Subjects With Treated Parkinson's Disease (PD) Long Term Study (LS-1). Available from: http://clinicaltrials.gov/ct2/show/NCT00449865.
9. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Movement Disorders 2001;16(3):448-58.
10. Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP. Epidemiology of Parkinson's disease. Journal of Neurology 2008;255(Suppl 5):18-32.
11. Beal MF. Mitochondria take center stage in aging and neurodegeneration. Annals of Neurology 2005;58(4):495-505.
12. Bender A, Samtleben W, Elstner M, Klopstock T. Long-term creatine supplementation is safe in aged patients with Parkinson disease. Nutrition Research 2008;28(3):172-8.
13. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. Journal of the Neurological Sciences 1973;20(4):415-55.
14. Boutron I, Tubach F, Giraudeau B, Ravaud P. Blinding was judged more difficult to achieve and maintain in nonpharmacologic than pharmacologic trials. Journal of Clinical Epidemiology 2004;57(6):543-50.
15. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurology 2006;5(6):525-35.
16. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al.Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68(5):384-6.
17. Greenamyre JT, Hastings TG. Biomedicine. Parkinson's--divergent causes, convergent mechanisms. Science 2004;304(5674):1120-2.
18. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
19. Klivenyi P, Gardian G, Calingasan NY, Yang L, Beal MF. Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. Journal of Molecular Neuroscience 2003;21(3):191-8.
20. Lawler JM, Barnes WS, Wu G, Song W, Demaree S. Direct antioxidant properties of creatine. Biochemical and Biophysical Research Communications 2002;290(1):47-52.
21. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009;373(9680):2055-66.
22. Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, et al.Creatine and cyclocreatine attenuate MPTP neurotoxicity. Experimental Neurology 1999;157(1):142-9.
23. Mattson MP, Pedersen WA, Duan W, Culmsee C, Camandola S. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Annals of the New York Academy of Sciences 1999;893:154-75.
24. Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, et al.Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 2003;60(8):1234-40.
25. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
26. Ryu H, Rosas HD, Hersch SM, Ferrante RJ. The therapeutic role of creatine in Huntington's disease. Pharmacology and Therapeutics 2005;108(2):193-207.
27. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004;363(9423):1783-93.
28. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 1995;273(5):408-12.
29. Sestili P, Martinelli C, Bravi G, Piccoli G, Curci R, Battistelli M, et al.Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity. Free Radical Biology and Medicine 2006;40(5):837-49.
30. Tarnopolsky MA, Beal MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Annals of Neurology 2001;49(5):561-74.
31. Tilley BC, Palesch YY, Kieburtz K, Ravina B, Huang P, Elm JJ, et al.Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology 2006;66(5):628-33.